A novel process for preparing thiazolidinediones preferably Pioglitazone as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.

The present invention provides a process for preparing 5-(acetylamino)-4-[(aminoiminomethyl)amino]-26-anhydro-345-trideoxy-D-glycero-D-galacto-non-enonic acid Formula (I) which process comprises reducing compound of Formula (IV) by Lindlar catalyst in presence of hydrogen to obtain compound of Formula (V). reacting compound of Formula (V) with pyrazole-1H-carboxamidine or its suitable salt to obtain compound of Formula (VIII). hydrolyzing the compound of Formula (VIII) to give compound of Formul...

The present invention relates to an amorphous form of vilazodone hydrochloride and process for the preparation of amorphous form of vilazodone hydrochloride. The invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD).

The present invention discloses an amorphous form of apixaban process of preparation and compositions thereof.

The present invention relates to Rasagiline acid addition salts having a particle size D(90) greater than 250 microns and D(50) greater than 100 microns with the proviso that acid addition salt is not mesylate. The invention also discloses a process for the preparation of such Rasagiline acid addition salts.

The present invention is related to a bilayer pharmaceutical composition comprising naproxen or a pharmaceutically acceptable salt thereof. The present invention is particularly related to a bilayer pharmaceutical composition comprising an immediate release component and a controlled release component of naproxen or a pharmaceutically acceptable salt thereof and the process for preparation thereof. Moreover the present invention is related to the treatment of rheumatoid arthritis oesteoarthritis...

The present invention discloses an amorphous form of apixaban process of preparation and compositions thereof.

The present invention relates to a method for treating reducing or preventing acne. In particular the present invention relates to methods for reducing the total number incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further the invention relates to reducing the incidence and severity of adverse events resulting from topical application of anti-acne agents resulting in improvement of skin tone. The method includes administering a ...

The present invention relates to a process for the preparation of 5-(4-[4-(5- cyano- 1 H-indol-3 -yl)butyl] piperazin- 1 -yl)benzofuran-2-carboxamide of Formula (1) or its pharmaceutically acceptable salt solvates or hydrates thereof. In particular the present invention provides a novel intermediate compound 5-(4-substitutedpiperazin- 1-yl)benzofuran-2-carboxamide of Formula (X). The present invention further provides solid state form of 5-(4-[4-(5-cyano-1H-indol-3- yl) butyl]piperazin-1-yl)benz...

The present invention relates to stable pharmaceutical compositions comprising nano size droplets of etodolac or salts thereof along with other pharmaceutically acceptable excipients. These compositions exhibit greater permeability and improved bioavailability leading to enhanced therapeutic activity. The invention also relates to processes for the preparation of such compositions.